What statement about the etonogestrel implant (Nexplanon®) is incorrect?

The statement that is found to be incorrect regarding the etonogestrel implant (Nexplanon®) is that it has the same potential adverse effects as combined oral contraceptives. While both methods are hormonal contraceptives and can produce side effects, the specific adverse effects differ significantly due to the differing hormone formulations and mechanisms of action.

The etonogestrel implant primarily releases a progestin hormone that can lead to specific side effects such as irregular bleeding or amenorrhea, which may not occur with combined oral contraceptives that contain both estrogen and progestin. Furthermore, combined oral contraceptives are associated with risks such as thromboembolic events due to the estrogen component, a risk not present with the progestin-only implant. This distinction makes it clear that the risk profiles for these two methods of contraception are not equivalent.

In contrast, amenorrhea is indeed common with Nexplanon®, and it is known for its effectiveness as a long-term contraceptive method, lasting up to three years. Additionally, the contraceptive effects of Nexplanon® are quickly reversible upon removal, making it an appealing option for those seeking reliable birth control without the long-term commitment associated with other types of birth control methods